Carregant...
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...
Guardat en:
| Publicat a: | BMC Hematol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://ncbi.nlm.nih.gov/pubmed/26167286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-015-0029-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|